[
    {
        "id": 0,
        "conceptType": "Drug",
        "name": "Brentuximab vedotin",
        "primaryCode": "ncit:C66944",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C66944",
                    "code": "C66944",
                    "name": "Brentuximab Vedotin",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "target CD30 antigens",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 1,
        "conceptType": "Drug",
        "name": "Dacarbazine",
        "primaryCode": "ncit:C411",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C411",
                    "code": "C411",
                    "name": "Dacarbazine",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Nonclassical alkylating chemotherapy",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 2,
        "conceptType": "Drug",
        "name": "Doxorubicin",
        "primaryCode": "ncit:C456",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C456",
                    "code": "C456",
                    "name": "Doxorubicin",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Topoisomerase inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 3,
        "conceptType": "Drug",
        "name": "Vinblastine",
        "primaryCode": "ncit:C930",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:",
                    "code": "C930",
                    "name": "Vinblastine",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Vinca alkaloid chemotherapy",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 4,
        "conceptType": "Drug",
        "name": "Everolimus",
        "primaryCode": "ncit:C48387",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C48387",
                    "code": "C48387",
                    "name": "Everolimus",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "PI3K/AKT/mTOR inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 5,
        "conceptType": "Drug",
        "name": "Exemestane",
        "primaryCode": "ncit:C1097",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C1097",
                    "code": "C1097",
                    "name": "Exemestane",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Aromatase inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Hormone therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 6,
        "conceptType": "Drug",
        "name": "Niraparib",
        "primaryCode": "ncit:C80059",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C80059",
                    "code": "C80059",
                    "name": "Niraparib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "PARP inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 7,
        "conceptType": "Drug",
        "name": "Abiraterone acetate",
        "primaryCode": "ncit:C68845",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C68845",
                    "code": "C68845",
                    "name": "Abiraterone Acetate",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Antiandrogen",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Hormone therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 8,
        "conceptType": "Drug",
        "name": "Prednisolone",
        "primaryCode": "ncit:C769",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C769",
                    "code": "C769",
                    "name": "Prednisolone",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Corticosteroid",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Hormone therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 9,
        "conceptType": "Drug",
        "name": "Alectinib",
        "primaryCode": "ncit:C101790",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C101790",
                    "code": "C101790",
                    "name": "Alectinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "ALK inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 10,
        "conceptType": "Drug",
        "name": "Brigatinib",
        "primaryCode": "ncit:C98831",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C98831",
                    "code": "C98831",
                    "name": "Brigatinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "ALK inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 11,
        "conceptType": "Drug",
        "name": "Bevacizumab",
        "primaryCode": "ncit:C2039",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C2039",
                    "code": "C2039",
                    "name": "Bevacizumab",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "VEGF inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 12,
        "conceptType": "Drug",
        "name": "Erlotinib",
        "primaryCode": "ncit:C65530",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C65530",
                    "code": "C65530",
                    "name": "Erlotinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "EGFR inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 13,
        "conceptType": "Drug",
        "name": "Avapritinib",
        "primaryCode": "ncit:C123827",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C123827",
                    "code": "C123827",
                    "name": "Avapritinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "KIT inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 14,
        "conceptType": "Drug",
        "name": "Inotuzumab ozogamicin",
        "primaryCode": "ncit:C71542",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C71542",
                    "code": "C71542",
                    "name": "Inotuzumab Ozogamicin",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "BCR-ABL inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 15,
        "conceptType": "Drug",
        "name": "Blinatumomab",
        "primaryCode": "ncit:C62528",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C62528",
                    "code": "C62528",
                    "name": "Blinatumomab",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "CD19 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Immunotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 16,
        "conceptType": "Drug",
        "name": "Bosutinib",
        "primaryCode": "ncit:C60809",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C60809",
                    "code": "C60809",
                    "name": "Bosutinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "BCR-ABL inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 17,
        "conceptType": "Drug",
        "name": "Binimetinib",
        "primaryCode": "ncit:C84865",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C84865",
                    "code": "C84865",
                    "name": "Binimetinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "MEK inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 18,
        "conceptType": "Drug",
        "name": "Encorafenib",
        "primaryCode": "ncit:C98283",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C98283",
                    "code": "C98283",
                    "name": "Encorafenib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "B-RAF inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 19,
        "conceptType": "Drug",
        "name": "Cetuximab",
        "primaryCode": "ncit:C1723",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C1723",
                    "code": "C1723",
                    "name": "Cetuximab",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "EGFR inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 20,
        "conceptType": "Drug",
        "name": "Vandetanib",
        "primaryCode": "ncit:C2737",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C2737",
                    "code": "C2737",
                    "name": "Vandetanib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "RET inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 21,
        "conceptType": "Drug",
        "name": "Cobimetinib",
        "primaryCode": "ncit:C68923",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C68923",
                    "code": "C68923",
                    "name": "Cobimetinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "MEK inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 22,
        "conceptType": "Drug",
        "name": "Vemurafenib",
        "primaryCode": "ncit:C64768",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C64768",
                    "code": "C64768",
                    "name": "Vemurafenib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "B-RAF inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 23,
        "conceptType": "Drug",
        "name": "Ramucirumab",
        "primaryCode": "ncit:C70792",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C70792",
                    "code": "C70792",
                    "name": "Ramucirumab",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "VEGF/VEGFR inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 24,
        "conceptType": "Drug",
        "name": "Docetaxel",
        "primaryCode": "ncit:C1526",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C1526",
                    "code": "C1526",
                    "name": "Docetaxel",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Taxane-based chemotherapy",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 25,
        "conceptType": "Drug",
        "name": "Trastuzumab",
        "primaryCode": "ncit:C1647",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C1647",
                    "code": "C1647",
                    "name": "Trastuzumab",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "HER2 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 26,
        "conceptType": "Drug",
        "name": "Trastuzumab deruxtecan",
        "primaryCode": "ncit:C128799",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C128799",
                    "code": "C128799",
                    "name": "Trastuzumab Deruxtecan",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "HER2 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 27,
        "conceptType": "Drug",
        "name": "Irinotecan",
        "primaryCode": "ncit:C62040",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C62040",
                    "code": "C62040",
                    "name": "Irinotecan",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Topoisomerase I inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 28,
        "conceptType": "Drug",
        "name": "Oxaliplatin",
        "primaryCode": "ncit:C1181",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C1181",
                    "code": "C1181",
                    "name": "Oxaliplatin",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Platinum-based chemotherapy",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 29,
        "conceptType": "Drug",
        "name": "Fluorouracil",
        "primaryCode": "ncit:C505",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C505",
                    "code": "C505",
                    "name": "Fluorouracil",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Thymidylate synthase inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 30,
        "conceptType": "Drug",
        "name": "Fulvestrant",
        "primaryCode": "ncit:C1379",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C1379",
                    "code": "C1379",
                    "name": "Fulvestrant",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Estrogen receptor inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Hormone therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 31,
        "conceptType": "Drug",
        "name": "Palbociclib",
        "primaryCode": "ncit:C49176",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C49176",
                    "code": "C49176",
                    "name": "Palbociclib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "CDK4/6 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 32,
        "conceptType": "Drug",
        "name": "Pralsetinib",
        "primaryCode": "ncit:C132295",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C132295",
                    "code": "C132295",
                    "name": "Pralsetinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "RET inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 33,
        "conceptType": "Drug",
        "name": "Gefitinib",
        "primaryCode": "ncit:C1855",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C1855",
                    "code": "C1855",
                    "name": "Gefitinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "EGFR inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 34,
        "conceptType": "Drug",
        "name": "Afatinib",
        "primaryCode": "ncit:C66940",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C66940",
                    "code": "C66940",
                    "name": "Afatinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "EGFR inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 35,
        "conceptType": "Drug",
        "name": "Paclitaxel",
        "primaryCode": "ncit:C1411",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C1411",
                    "code": "C1411",
                    "name": "Paclitaxel",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Taxane-based chemotherapy",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 36,
        "conceptType": "Drug",
        "name": "Anastrozole",
        "primaryCode": "ncit:C1607",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C1607",
                    "code": "C1607",
                    "name": "Anastrozole",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Aromatase inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Hormone therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 37,
        "conceptType": "Drug",
        "name": "Carboplatin",
        "primaryCode": "ncit:C1282",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C1282",
                    "code": "C1282",
                    "name": "Carboplatin",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Platinum-based chemotherapy",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 38,
        "conceptType": "Drug",
        "name": "Capecitabine",
        "primaryCode": "ncit:C1794",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C1794",
                    "code": "C1794",
                    "name": "Capecitabine",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Thymidylate synthase inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 39,
        "conceptType": "Drug",
        "name": "Cisplatin",
        "primaryCode": "ncit:C376",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C376",
                    "code": "C376",
                    "name": "Cisplatin",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Platinum-based chemotherapy",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 40,
        "conceptType": "Drug",
        "name": "Letrozole",
        "primaryCode": "ncit:C1527",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C1527",
                    "code": "C1527",
                    "name": "Letrozole",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Aromatase inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Hormone therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 41,
        "conceptType": "Drug",
        "name": "Imatinib",
        "primaryCode": "ncit:C62035",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C62035",
                    "code": "C62035",
                    "name": "Imatinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "BCR-ABL inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 42,
        "conceptType": "Drug",
        "name": "Imatinib",
        "primaryCode": "ncit:",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:",
                    "code": "",
                    "name": "",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "c-Kit inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 43,
        "conceptType": "Drug",
        "name": "Ponatinib",
        "primaryCode": "ncit:C95777",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C95777",
                    "code": "C95777",
                    "name": "Ponatinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "BCR-ABL inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 44,
        "conceptType": "Drug",
        "name": "Durvalumab",
        "primaryCode": "ncit:C103194",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C103194",
                    "code": "C103194",
                    "name": "Durvalumab",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "PD-1/PD-L1 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Immunotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 45,
        "conceptType": "Drug",
        "name": "Tremelimumab",
        "primaryCode": "ncit:C49085",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C49085",
                    "code": "C49085",
                    "name": "Tremelimumab",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "CTLA-4 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Immunotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 46,
        "conceptType": "Drug",
        "name": "Olaparib",
        "primaryCode": "ncit:C71721",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C71721",
                    "code": "C71721",
                    "name": "Olaparib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "PARP inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 47,
        "conceptType": "Drug",
        "name": "Dostarlimab",
        "primaryCode": "ncit:C126799",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C126799",
                    "code": "C126799",
                    "name": "Dostarlimab",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "PD-1/PD-L1 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Immunotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 48,
        "conceptType": "Drug",
        "name": "Pembrolizumab",
        "primaryCode": "ncit:C106432",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C106432",
                    "code": "C106432",
                    "name": "Pembrolizumab",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "PD-1/PD-L1 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Immunotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 49,
        "conceptType": "Drug",
        "name": "Pemetrexed",
        "primaryCode": "ncit:C61614",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C61614",
                    "code": "C61614",
                    "name": "Pemetrexed",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Antifolate",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 50,
        "conceptType": "Drug",
        "name": "Gemcitabine",
        "primaryCode": "ncit:C66876",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C66876",
                    "code": "C66876",
                    "name": "Gemcitabine",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Antimetabolite",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 51,
        "conceptType": "Drug",
        "name": "Nab-paclitaxel",
        "primaryCode": "ncit:C2688",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C2688",
                    "code": "C2688",
                    "name": "Nab-paclitaxel",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Taxane-based chemotherapy",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 52,
        "conceptType": "Drug",
        "name": "Trastuzumab emtansine",
        "primaryCode": "ncit:C82492",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C82492",
                    "code": "C82492",
                    "name": "Trastuzumab Emtansine",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "HER2 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 53,
        "conceptType": "Drug",
        "name": "Ribociclib",
        "primaryCode": "ncit:C95701",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C95701",
                    "code": "C95701",
                    "name": "Ribociclib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "CDK4/6 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 54,
        "conceptType": "Drug",
        "name": "Adagrasib",
        "primaryCode": "ncit:C157493",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C157493",
                    "code": "C157493",
                    "name": "Adagrasib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "RAS inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 55,
        "conceptType": "Drug",
        "name": "Cemiplimab",
        "primaryCode": "ncit:C121540",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C121540",
                    "code": "C121540",
                    "name": "Cemiplimab",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "PD-1/PD-L1 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Immunotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 56,
        "conceptType": "Drug",
        "name": "Lorlatinib",
        "primaryCode": "ncit:C113655",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C113655",
                    "code": "C113655",
                    "name": "Lorlatinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "ALK inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 57,
        "conceptType": "Drug",
        "name": "Sotorasib",
        "primaryCode": "ncit:C154287",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C154287",
                    "code": "C154287",
                    "name": "Sotorasib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "RAS inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 58,
        "conceptType": "Drug",
        "name": "Futibatinib",
        "primaryCode": "ncit:C114283",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C114283",
                    "code": "C114283",
                    "name": "Futibatinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "FGFR inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 59,
        "conceptType": "Drug",
        "name": "Cyclophosphamide",
        "primaryCode": "ncit:C405",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C405",
                    "code": "C405",
                    "name": "Cyclophosphamide",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Alkylating chemotherapy",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 60,
        "conceptType": "Drug",
        "name": "Rituximab",
        "primaryCode": "ncit:C1702",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C1702",
                    "code": "C1702",
                    "name": "Rituximab",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "CD20 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Immunotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 61,
        "conceptType": "Drug",
        "name": "Vincristine",
        "primaryCode": "ncit:C933",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C933",
                    "code": "C933",
                    "name": "Vincristine",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Vinca alkaloid chemotherapy",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 62,
        "conceptType": "Drug",
        "name": "Corticosteroid",
        "primaryCode": "ncit:C2322",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C2322",
                    "code": "C2322",
                    "name": "Corticosteroid",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Anti-inflammatory",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Hormone therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 63,
        "conceptType": "Drug",
        "name": "Cytarabine",
        "primaryCode": "ncit:C408",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C408",
                    "code": "C408",
                    "name": "Cytarabine",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "DNA Polymerase inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 64,
        "conceptType": "Drug",
        "name": "Etoposide",
        "primaryCode": "ncit:C491",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C491",
                    "code": "C491",
                    "name": "Etoposide",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Topoisomerase inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 65,
        "conceptType": "Drug",
        "name": "Methotrexate",
        "primaryCode": "ncit:C642",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C642",
                    "code": "C642",
                    "name": "Methotrexate",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Antifolate",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 66,
        "conceptType": "Drug",
        "name": "Trametinib",
        "primaryCode": "ncit:C77908",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C77908",
                    "code": "C77908",
                    "name": "Trametinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "MEK inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 67,
        "conceptType": "Drug",
        "name": "Dabrafenib",
        "primaryCode": "ncit:C82386",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C82386",
                    "code": "C82386",
                    "name": "Dabrafenib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "B-RAF inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 68,
        "conceptType": "Drug",
        "name": "Daunorubicin",
        "primaryCode": "ncit:C62091",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C62091",
                    "code": "C62091",
                    "name": "Daunorubicin",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "DNA Polymerase inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 69,
        "conceptType": "Drug",
        "name": "Gemtuzumab ozogamicin",
        "primaryCode": "ncit:C1806",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C1806",
                    "code": "C1806",
                    "name": "Gemtuzumab Ozogamicin",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "CD33 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Immunotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 70,
        "conceptType": "Drug",
        "name": "Neratinib",
        "primaryCode": "ncit:C49094",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C49094",
                    "code": "C49094",
                    "name": "Neratinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "HER2 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 71,
        "conceptType": "Drug",
        "name": "Ipilimumab",
        "primaryCode": "ncit:C2654",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C2654",
                    "code": "C2654",
                    "name": "Ipilimumab",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "CTLA-4 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Immunotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 72,
        "conceptType": "Drug",
        "name": "Nivolumab",
        "primaryCode": "ncit:C68814",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C68814",
                    "code": "C68814",
                    "name": "Nivolumab",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "PD-1/PD-L1 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Immunotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 73,
        "conceptType": "Drug",
        "name": "Relatlimab",
        "primaryCode": "ncit:C111999",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C111999",
                    "code": "C111999",
                    "name": "Relatlimab",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "LAG-3 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Immunotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 74,
        "conceptType": "Drug",
        "name": "Elacestrant",
        "primaryCode": "ncit:C120211",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C120211",
                    "code": "C120211",
                    "name": "Elacestrant",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "ER signaling inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Hormone therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 75,
        "conceptType": "Drug",
        "name": "Pertuzumab",
        "primaryCode": "ncit:C38692",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C38692",
                    "code": "C38692",
                    "name": "Pertuzumab",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "HER2 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 76,
        "conceptType": "Drug",
        "name": "Epirubicin",
        "primaryCode": "ncit:C62028",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C62028",
                    "code": "C62028",
                    "name": "Epirubicin",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Topoisomerase inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 77,
        "conceptType": "Drug",
        "name": "Alpelisib",
        "primaryCode": "ncit:C94214",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C94214",
                    "code": "C94214",
                    "name": "Alpelisib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "PI3K/AKT/mTOR inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 78,
        "conceptType": "Drug",
        "name": "Selpercatinib",
        "primaryCode": "ncit:C134987",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C134987",
                    "code": "C134987",
                    "name": "Selpercatinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "RET inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 79,
        "conceptType": "Drug",
        "name": "Lenalidomide",
        "primaryCode": "ncit:C2668",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C2668",
                    "code": "C2668",
                    "name": "Lenalidomide",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Angiogenesis inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 80,
        "conceptType": "Drug",
        "name": "Entrectinib",
        "primaryCode": "ncit:C114984",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C114984",
                    "code": "C114984",
                    "name": "Entrectinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "ROS1 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 81,
        "conceptType": "Drug",
        "name": "Entrectinib",
        "primaryCode": "ncit:",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:",
                    "code": "",
                    "name": "",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "TRK inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 82,
        "conceptType": "Drug",
        "name": "Midostaurin",
        "primaryCode": "ncit:C1872",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C1872",
                    "code": "C1872",
                    "name": "Midostaurin",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "FLT3 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 83,
        "conceptType": "Drug",
        "name": "Asciminib",
        "primaryCode": "ncit:C114494",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C114494",
                    "code": "C114494",
                    "name": "Asciminib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "BCR-ABL inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 84,
        "conceptType": "Drug",
        "name": "Dasatinib",
        "primaryCode": "ncit:C38713",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C38713",
                    "code": "C38713",
                    "name": "Dasatinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "BCR-ABL inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 85,
        "conceptType": "Drug",
        "name": "Capmatinib",
        "primaryCode": "ncit:C90564",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C90564",
                    "code": "C90564",
                    "name": "Capmatinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "MET inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 86,
        "conceptType": "Drug",
        "name": "Osimertinib",
        "primaryCode": "ncit:C116377",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C116377",
                    "code": "C116377",
                    "name": "Osimertinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "EGFR inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 87,
        "conceptType": "Drug",
        "name": "Talazoparib",
        "primaryCode": "ncit:C95733",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C95733",
                    "code": "C95733",
                    "name": "Talazoparib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "PARP inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 88,
        "conceptType": "Drug",
        "name": "Nilotinib",
        "primaryCode": "ncit:C48375",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C48375",
                    "code": "C48375",
                    "name": "Nilotinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "BCR-ABL inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 89,
        "conceptType": "Drug",
        "name": "Atezolizumab",
        "primaryCode": "ncit:C106250",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C106250",
                    "code": "C106250",
                    "name": "Atezolizumab",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "PD-1/PD-L1 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Immunotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 90,
        "conceptType": "Drug",
        "name": "Tepotinib",
        "primaryCode": "ncit:C88314",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C88314",
                    "code": "C88314",
                    "name": "Tepotinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "MET inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 91,
        "conceptType": "Drug",
        "name": "Azacitidine",
        "primaryCode": "ncit:C288",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C288",
                    "code": "C288",
                    "name": "Azacitidine",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Hypomethylating agent chemotherapy",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 92,
        "conceptType": "Drug",
        "name": "Ivosidenib",
        "primaryCode": "ncit:C114383",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C114383",
                    "code": "C114383",
                    "name": "Ivosidenib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "IDH1 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 93,
        "conceptType": "Drug",
        "name": "Arsenic trioxide",
        "primaryCode": "ncit:C1005",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C1005",
                    "code": "C1005",
                    "name": "Arsenic Trioxide",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "PML::RARA inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 94,
        "conceptType": "Drug",
        "name": "Sacituzumab govitecan",
        "primaryCode": "ncit:C102783",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C102783",
                    "code": "C102783",
                    "name": "Sacituzumab Govitecan",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Topoisomerase inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 95,
        "conceptType": "Drug",
        "name": "Tucatinib",
        "primaryCode": "ncit:C77896",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C77896",
                    "code": "C77896",
                    "name": "Tucatinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "HER2 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 96,
        "conceptType": "Drug",
        "name": "Lapatinib",
        "primaryCode": "ncit:C26653",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C26653",
                    "code": "C26653",
                    "name": "Lapatinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "HER2 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 97,
        "conceptType": "Drug",
        "name": "Panitumumab",
        "primaryCode": "ncit:C1857",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C1857",
                    "code": "C1857",
                    "name": "Panitumumab",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "EGFR inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 98,
        "conceptType": "Drug",
        "name": "Venetoclax",
        "primaryCode": "ncit:C103147",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C103147",
                    "code": "C103147",
                    "name": "Venetoclax",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "BCL2 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 99,
        "conceptType": "Drug",
        "name": "Abemaciclib",
        "primaryCode": "ncit:C97660",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C97660",
                    "code": "C97660",
                    "name": "Abemaciclib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "CDK4/6 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 100,
        "conceptType": "Drug",
        "name": "Larotrectinib",
        "primaryCode": "ncit:C115977",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C115977",
                    "code": "C115977",
                    "name": "Larotrectinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "TRK inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 101,
        "conceptType": "Drug",
        "name": "Dacomitinib",
        "primaryCode": "ncit:C53398",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C53398",
                    "code": "C53398",
                    "name": "Dacomitinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "EGFR inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 102,
        "conceptType": "Drug",
        "name": "Crizotinib",
        "primaryCode": "ncit:C74061",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C74061",
                    "code": "C74061",
                    "name": "Crizotinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "ALK inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 103,
        "conceptType": "Drug",
        "name": "Crizotinib",
        "primaryCode": "ncit:",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:",
                    "code": "",
                    "name": "",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "ROS1 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 104,
        "conceptType": "Drug",
        "name": "Gilteritinib",
        "primaryCode": "ncit:C116722",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C116722",
                    "code": "C116722",
                    "name": "Gilteritinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "FLT3 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 105,
        "conceptType": "Drug",
        "name": "Idelalisib",
        "primaryCode": "ncit:C78825",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C78825",
                    "code": "C78825",
                    "name": "Idelalisib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "PI3K/AKT/mTOR inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 106,
        "conceptType": "Drug",
        "name": "Ceritinib",
        "primaryCode": "ncit:C115112",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C115112",
                    "code": "C115112",
                    "name": "Ceritinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "ALK inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 107,
        "conceptType": "Drug",
        "name": "Tislelizumab",
        "primaryCode": "ncit:C121775",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C121775",
                    "code": "C121775",
                    "name": "Tislelizumab",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "PD-1/PD-L1 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Immunotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 108,
        "conceptType": "Drug",
        "name": "Amivantamab",
        "primaryCode": "ncit:C124993",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C124993",
                    "code": "C124993",
                    "name": "Amivantamab",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "EGFR inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 109,
        "conceptType": "Drug",
        "name": "Capivasertib",
        "primaryCode": "ncit:C102564",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C102564",
                    "code": "C102564",
                    "name": "Capivasertib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "PI3K/AKT/mTOR inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 110,
        "conceptType": "Drug",
        "name": "Erdafitinib",
        "primaryCode": "ncit:C103273",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C103273",
                    "code": "C103273",
                    "name": "Erdafitinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "FGFR inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 111,
        "conceptType": "Drug",
        "name": "Zolbetuximab",
        "primaryCode": "ncit:C85475",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C85475",
                    "code": "C85475",
                    "name": "Zolbetuximab",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "CLDN18.2 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Immunotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 112,
        "conceptType": "Drug",
        "name": "Neratinib",
        "primaryCode": "ncit:C49094",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C49094",
                    "code": "C49094",
                    "name": "Neratinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "ER Signaling inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 113,
        "conceptType": "Drug",
        "name": "Zanubrutinib",
        "primaryCode": "ncit:C141428",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C141428",
                    "code": "C141428",
                    "name": "Zanubrutinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "BTK inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 114,
        "conceptType": "Drug",
        "name": "Acalabrutinib",
        "primaryCode": "ncit:C113442",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C113442",
                    "code": "C113442",
                    "name": "Acalabrutinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "BTK inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 115,
        "conceptType": "Drug",
        "name": "Ibrutinib",
        "primaryCode": "ncit:C81934",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C81934",
                    "code": "C81934",
                    "name": "Ibrutinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "BTK inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 116,
        "conceptType": "Drug",
        "name": "Ifosfamide",
        "primaryCode": "ncit:C564",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C564",
                    "code": "C564",
                    "name": "Ifosfamide",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Alkylating chemotherapy",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 117,
        "conceptType": "Drug",
        "name": "Vinorelbine",
        "primaryCode": "ncit:C1275",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C1275",
                    "code": "C1275",
                    "name": "Vinorelbine",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Vinca alkaloid chemotherapy",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 118,
        "conceptType": "Drug",
        "name": "Doxorubicin",
        "primaryCode": "ncit:",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:",
                    "code": "",
                    "name": "",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Topoisomerase inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 119,
        "conceptType": "Drug",
        "name": "Tamoxifen",
        "primaryCode": "ncit:C62078",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C62078",
                    "code": "C62078",
                    "name": "Tamoxifen",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Estrogen receptor inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Hormone therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 120,
        "conceptType": "Drug",
        "name": "Ofatumumab",
        "primaryCode": "ncit:C66952",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C66952",
                    "code": "C66952",
                    "name": "Ofatumumab",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "CD20 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Immunotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 121,
        "conceptType": "Drug",
        "name": "Bendamustine",
        "primaryCode": "ncit:C73261",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C73261",
                    "code": "C73261",
                    "name": "Bendamustine",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Alkylating chemotherapy",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 122,
        "conceptType": "Drug",
        "name": "Prednisolone",
        "primaryCode": "ncit:",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:",
                    "code": "",
                    "name": "",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Corticosteroid",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Steroid",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 123,
        "conceptType": "Drug",
        "name": "Chlorambucil",
        "primaryCode": "ncit:C362",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C362",
                    "code": "C362",
                    "name": "Chlorambucil",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Alkylating chemotherapy",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 124,
        "conceptType": "Drug",
        "name": "Mitoxantrone",
        "primaryCode": "ncit:C62050",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C62050",
                    "code": "C62050",
                    "name": "Mitoxantrone",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Topoisomerase inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 125,
        "conceptType": "Drug",
        "name": "Interferon alpha",
        "primaryCode": "ncit:C20494",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C20494",
                    "code": "C20494",
                    "name": "Interferon Alpha",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Cytokine stimulation",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Immunotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 126,
        "conceptType": "Drug",
        "name": "Enasidenib",
        "primaryCode": "ncit:C111573",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C111573",
                    "code": "C111573",
                    "name": "Enasidenib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "IDH2 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 127,
        "conceptType": "Drug",
        "name": "Infigratinib",
        "primaryCode": "ncit:C88302",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C88302",
                    "code": "C88302",
                    "name": "Infigratinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "FGFR2 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 128,
        "conceptType": "Drug",
        "name": "Margetuximab",
        "primaryCode": "ncit:",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C91733",
                    "code": "C91733",
                    "name": "Margetuximab",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "ER signaling inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Hormone therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 129,
        "conceptType": "Drug",
        "name": "Eribulin",
        "primaryCode": "ncit:C96748",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C96748",
                    "code": "C96748",
                    "name": "Eribulin",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Tubulin polymerization inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 130,
        "conceptType": "Drug",
        "name": "Mobocertinib",
        "primaryCode": "ncit:C126752",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C126752",
                    "code": "C126752",
                    "name": "Mobocertinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "EGFR inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 131,
        "conceptType": "Drug",
        "name": "Olutasidenib",
        "primaryCode": "ncit:C129687",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C129687",
                    "code": "C129687",
                    "name": "Olutasidenib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "IDH1 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 132,
        "conceptType": "Drug",
        "name": "Lenvatinib",
        "primaryCode": "ncit:C95124",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C95124",
                    "code": "C95124",
                    "name": "Lenvatinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "VEGFR inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 133,
        "conceptType": "Drug",
        "name": "Pemigatinib",
        "primaryCode": "ncit:C121553",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C121553",
                    "code": "C121553",
                    "name": "Pemigatinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "FGFR inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 134,
        "conceptType": "Drug",
        "name": "Repotrectinib",
        "primaryCode": "ncit:C133821",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C133821",
                    "code": "C133821",
                    "name": "Repotrectinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "ROS inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 135,
        "conceptType": "Drug",
        "name": "Fludarabine",
        "primaryCode": "ncit:C1094",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C1094",
                    "code": "C1094",
                    "name": "Fludarabine",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Antimetabolite",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 136,
        "conceptType": "Drug",
        "name": "Rucaparib",
        "primaryCode": "ncit:C137800",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C137800",
                    "code": "C137800",
                    "name": "Rucaparib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "PARP inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 137,
        "conceptType": "Drug",
        "name": "Tazemetostat",
        "primaryCode": "ncit:C107506",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C107506",
                    "code": "C107506",
                    "name": "Tazemetostat",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "EZH2 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 138,
        "conceptType": "Drug",
        "name": "Enzalutamide",
        "primaryCode": "ncit:C71744",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C71744",
                    "code": "C71744",
                    "name": "Enzalutamide",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Antiandrogen",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Hormone therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 139,
        "conceptType": "Drug",
        "name": "Lazertinib",
        "primaryCode": "ncit:C148147",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C148147",
                    "code": "C148147",
                    "name": "Lazertinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "EGFR inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 140,
        "conceptType": "Drug",
        "name": "Mirvetuximab soravtansine",
        "primaryCode": "ncit:C102566",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C102566",
                    "code": "C102566",
                    "name": "Mirvetuximab Soravtansine",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Folate receptor-alpha inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Chemotherapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 141,
        "conceptType": "Drug",
        "name": "Tovorafenib",
        "primaryCode": "ncit:C106254",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C106254",
                    "code": "C106254",
                    "name": "Tovorafenib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "B-RAF inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 142,
        "conceptType": "Drug",
        "name": "Vorasidenib",
        "primaryCode": "ncit:C152914",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C152914",
                    "code": "C152914",
                    "name": "Vorasidenib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "IDH1/2 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 143,
        "conceptType": "Drug",
        "name": "Goserelin",
        "primaryCode": "ncit:C1374",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C1374",
                    "code": "C1374",
                    "name": "Goserelin",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "Gonadotropin-releasing hormone (GnRH) agonist",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Hormone therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 144,
        "conceptType": "Drug",
        "name": "Inavolisib",
        "primaryCode": "ncit:C132166",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C132166",
                    "code": "C132166",
                    "name": "Inavolisib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "PI3K/AKT/mTOR inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 145,
        "conceptType": "Drug",
        "name": "Zanidatamab",
        "primaryCode": "ncit:C130010",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C130010",
                    "code": "C130010",
                    "name": "Zanidatamab",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "ER signaling inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 146,
        "conceptType": "Drug",
        "name": "Zenocutuzumab",
        "primaryCode": "ncit:C152948",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C152948",
                    "code": "C152948",
                    "name": "Zenocutuzumab",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "NRG1 inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    },
    {
        "id": 147,
        "conceptType": "Drug",
        "name": "Ensartinib",
        "primaryCode": "ncit:C102754",
        "mappings": [
            {
                "coding": {
                    "id": "ncit:C102754",
                    "code": "C102754",
                    "name": "Ensartinib",
                    "system": "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/",
                    "systemVersion": "25.01d"
                },
                "relation": "exactMatch"
            }
        ],
        "extensions": [
            {
                "name": "therapy_strategy",
                "value": "ALK inhibition",
                "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
                "name": "therapy_type",
                "value": "Targeted therapy",
                "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
        ]
    }
]